Guiqin Hou

652 total citations
24 papers, 539 citations indexed

About

Guiqin Hou is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Guiqin Hou has authored 24 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 3 papers in Pathology and Forensic Medicine and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Guiqin Hou's work include PI3K/AKT/mTOR signaling in cancer (9 papers), Cancer-related gene regulation (7 papers) and Cancer Mechanisms and Therapy (3 papers). Guiqin Hou is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (9 papers), Cancer-related gene regulation (7 papers) and Cancer Mechanisms and Therapy (3 papers). Guiqin Hou collaborates with scholars based in China, New Zealand and India. Guiqin Hou's co-authors include Zhaoming Lu, Lexun Xue, Tianli Fan, Fang Tian, Yandan Ren, Mingyue Liu, Fanghua Gong, Mingzhi Zhang, Wen Zhao and Hongtao Liu and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Biochemical Pharmacology.

In The Last Decade

Guiqin Hou

23 papers receiving 534 citations

Peers

Guiqin Hou

ONCOL

PRM

EPIDE

Jiapeng Xu China

Zunqi Hu China

Ranadip Mandal Germany

Olga Surova Sweden

Hae Jong Kim South Korea

Cristina Andreani Italy

Yichao Gan China

Meihui Xia China

Z. Peter Wang China

Fugen Shangguan China

Jiapeng Xu China

Guiqin Hou

279 ×0.7

135 ×1.4

64 ×0.8

ONCOL

57 ×0.8

PRM

60 ×1.0

EPIDE

Citations per year, relative to Guiqin Hou Guiqin Hou (= 1×) peers Jiapeng Xu

Countries citing papers authored by Guiqin Hou

Since Specialization

Citations

This map shows the geographic impact of Guiqin Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guiqin Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guiqin Hou more than expected).

Fields of papers citing papers by Guiqin Hou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guiqin Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guiqin Hou. The network helps show where Guiqin Hou may publish in the future.

Co-authorship network of co-authors of Guiqin Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Guiqin Hou. A scholar is included among the top collaborators of Guiqin Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guiqin Hou. Guiqin Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hou, Guiqin, et al.. (2023). NRG1 promotes tumorigenesis and metastasis and afatinib treatment efficiency is enhanced by NRG1 inhibition in esophageal squamous cell carcinoma. Biochemical Pharmacology. 218. 115920–115920. 5 indexed citations

Lu, Zhaoming, Yalin Zhang, Yujia Xu, et al.. (2021). mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma. Molecular Biology Reports. 49(1). 451–461. 6 indexed citations

Liu, Shu, Hang Zhao, Wei Tao Huang, et al.. (2020). Resveratrol Upregulates mmu-miR-363-3p via the PI3K-Akt Pathway to Improve Insulin Resistance Induced by a High-Fat Diet in Mice. SHILAP Revista de lepidopterología. 1 indexed citations

Lu, Zhaoming, Xiaojing Shi, Fanghua Gong, et al.. (2020). RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma. Acta Pharmaceutica Sinica B. 10(6). 1004–1019. 23 indexed citations

Lu, Zhaoming, Yandan Ren, Li Yang, et al.. (2020). Inhibiting autophagy enhances sulforaphane-induced apoptosis via targeting NRF2 in esophageal squamous cell carcinoma. Acta Pharmaceutica Sinica B. 11(5). 1246–1260. 40 indexed citations

Hou, Guiqin, Yi‐Ru Bai, Yandan Ren, et al.. (2020). Inhibition of autophagy improves resistance and enhances sensitivity of gastric cancer cells to cisplatin. Canadian Journal of Physiology and Pharmacology. 98(7). 449–458. 16 indexed citations

Hou, Guiqin, Qiang Zhao, Miaomiao Zhang, et al.. (2019). LSD1 regulates Notch and PI3K/Akt/mTOR pathways through binding the promoter regions of Notch target genes in esophageal squamous cell carcinoma. SHILAP Revista de lepidopterología. 1 indexed citations

Tang, Rong, Yipeng Wang, Wei Li, et al.. (2019). Multiple extramedullary plasmacytomas of the trachea and pharyngeal tissue: a case report and literature review. SHILAP Revista de lepidopterología.

Hou, Guiqin, Qi Zhao, Mengying Zhang, et al.. (2019). <p>LSD1 regulates Notch and PI3K/Akt/mTOR pathways through binding the promoter regions of Notch target genes in esophageal squamous cell carcinoma</p>. OncoTargets and Therapy. Volume 12. 5215–5225. 16 indexed citations

10.

Lu, Zhaoming, Yandan Ren, Mengying Zhang, et al.. (2018). FLI-06 suppresses proliferation, induces apoptosis and cell cycle arrest by targeting LSD1 and Notch pathway in esophageal squamous cell carcinoma cells. Biomedicine & Pharmacotherapy. 107. 1370–1376. 23 indexed citations

11.

Hou, Guiqin, Qi Zhao, Mingjie Zhang, et al.. (2018). Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma. Biomedicine & Pharmacotherapy. 106. 1348–1356. 29 indexed citations

12.

Liu, Mingyue, Xiqing Li, Tianhui Gao, et al.. (2018). Subcellular localization of Klf4 in non-small cell lung cancer and its clinical significance. Biomedicine & Pharmacotherapy. 99. 480–485. 13 indexed citations

13.

Lu, Zhaoming, et al.. (2016). Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell Carcinoma. Journal of Immunology Research. 2016. 1–9. 10 indexed citations

14.

Gong, Fanghua, Guiqin Hou, Hongtao Liu, & Mingzhi Zhang. (2015). Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma. Medical Oncology. 32(2). 455–455. 39 indexed citations

15.

Wang, Cong, Liping Jiang, Saiqi Wang, et al.. (2015). The Antitumor Activity of the Novel Compound Jesridonin on Human Esophageal Carcinoma Cells. PLoS ONE. 10(6). e0130284–e0130284. 35 indexed citations

16.

Hou, Guiqin, Shuai Yang, Yuanyuan Zhou, et al.. (2014). Targeted Inhibition of mTOR Signaling Improves Sensitivity of Esophageal Squamous Cell Carcinoma Cells to Cisplatin. Journal of Immunology Research. 2014. 1–9. 23 indexed citations

17.

Hou, Guiqin, Zhaoming Lu, Mingyue Liu, Hong‐Min Liu, & Lexun Xue. (2010). Mutational Analysis of the PTEN Gene and Its Effects in Esophageal Squamous Cell Carcinoma. Digestive Diseases and Sciences. 56(5). 1315–1322. 11 indexed citations

18.

Wang, Tianyun, Guiqin Hou, Yuang Wang, & Li Xue. (2010). Characterization and heterologous expression of a new matrix attachment region binding protein from the unicellular green alga Dunaliella salina. The Journal of Biochemistry. 148(6). 651–658. 3 indexed citations

19.

Hou, Guiqin, et al.. (2009). mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. Cancer Letters. 290(2). 248–254. 42 indexed citations

20.

Hou, Guiqin, et al.. (2007). An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Letters. 253(2). 236–248. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact